154 related articles for article (PubMed ID: 12076307)
1. Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists.
Nilvebrant L
Pharmacol Toxicol; 2002 May; 90(5):260-7. PubMed ID: 12076307
[TBL] [Abstract][Full Text] [Related]
2. Tolterodine--a new bladder-selective antimuscarinic agent.
Nilvebrant L; Andersson KE; Gillberg PG; Stahl M; Sparf B
Eur J Pharmacol; 1997 May; 327(2-3):195-207. PubMed ID: 9200560
[TBL] [Abstract][Full Text] [Related]
3. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine.
Nilvebrant L; Gillberg PG; Sparf B
Pharmacol Toxicol; 1997 Oct; 81(4):169-72. PubMed ID: 9353847
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
Gillberg PG; Sundquist S; Nilvebrant L
Eur J Pharmacol; 1998 May; 349(2-3):285-92. PubMed ID: 9671109
[TBL] [Abstract][Full Text] [Related]
5. Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.
Nilvebrant L; Hallén B; Larsson G
Life Sci; 1997; 60(13-14):1129-36. PubMed ID: 9121357
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of tolterodine on human isolated urinary bladder.
Yono M; Yoshida M; Wada Y; Kikukawa H; Takahashi W; Inadome A; Seshita H; Ueda S
Eur J Pharmacol; 1999 Mar; 368(2-3):223-30. PubMed ID: 10193658
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of novel antimuscarinic drugs on human detrusor smooth muscle.
Yono M; Yoshida M; Takahashi W; Inadome A; Ueda S
BJU Int; 2000 Oct; 86(6):719-25. PubMed ID: 11069384
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Ohtake A; Saitoh C; Yuyama H; Ukai M; Okutsu H; Noguchi Y; Hatanaka T; Suzuki M; Sato S; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):54-8. PubMed ID: 17202659
[TBL] [Abstract][Full Text] [Related]
9. Different responses to drugs against overactive bladder in detrusor muscle of pig, guinea pig and mouse.
Wüst M; Averbeck B; Reif S; Bräter M; Ravens U
Eur J Pharmacol; 2002 Nov; 454(1):59-69. PubMed ID: 12409006
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.
Salcedo C; Davalillo S; Cabellos J; Lagunas C; Balsa D; Pérez-Del-Pulgar S; Ballarín M; Fernández A
Br J Pharmacol; 2009 Mar; 156(5):807-17. PubMed ID: 19222482
[TBL] [Abstract][Full Text] [Related]
11. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological effects of propiverine and its active metabolite, M-1, on isolated human urinary bladder smooth muscle, and on bladder contraction in rats.
Sugiyama Y; Yoshida M; Masunaga K; Satoji Y; Maeda Y; Nagata T; Inadome A; Ueda S
Int J Urol; 2008 Jan; 15(1):76-81. PubMed ID: 18184179
[TBL] [Abstract][Full Text] [Related]
13. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
Kobayashi S; Ikeda K; Miyata K
Life Sci; 2004 Jan; 74(7):843-53. PubMed ID: 14659973
[TBL] [Abstract][Full Text] [Related]
14. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction.
Kaiho Y; Nishiguchi J; Kwon DD; Chancellor MB; Arai Y; Snyder PB; Yoshimura N
BJU Int; 2008 Mar; 101(5):615-20. PubMed ID: 18070178
[TBL] [Abstract][Full Text] [Related]
15. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
Kim Y; Yoshimura N; Masuda H; de Miguel F; Chancellor MB
Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029
[TBL] [Abstract][Full Text] [Related]
16. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
Kobayashi F; Yageta Y; Segawa M; Matsuzawa S
Arzneimittelforschung; 2007; 57(2):92-100. PubMed ID: 17396619
[TBL] [Abstract][Full Text] [Related]
17. Effects of ritobegron (KUC-7483), a novel β3-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine.
Maruyama I; Yonekubo S; Tatemichi S; Maruyama K; Hoyano Y; Yamazaki Y; Kusama H
J Smooth Muscle Res; 2012; 48(5-6):115-24. PubMed ID: 23538508
[TBL] [Abstract][Full Text] [Related]
18. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
Shannon HE; Bymaster FP; Calligaro DO; Greenwood B; Mitch CH; Sawyer BD; Ward JS; Wong DT; Olesen PH; Sheardown MJ; Swedberg MD; Suzdak PD; Sauerberg P
J Pharmacol Exp Ther; 1994 Apr; 269(1):271-81. PubMed ID: 7909557
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibitory effect of imidafenacin and 5-hydroxymethyl tolterodine on capsaicin sensitive C fibers of the primary bladder mechanosensitive afferent nerves in the rat.
Aizawa N; Ito H; Sugiyama R; Fujimura T; Suzuki M; Fukuhara H; Homma Y; Igawa Y
J Urol; 2015 Apr; 193(4):1423-32. PubMed ID: 25219701
[TBL] [Abstract][Full Text] [Related]
20. Clinical experiences with tolterodine.
Nilvebrant L
Life Sci; 2001 Apr; 68(22-23):2549-56. PubMed ID: 11392625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
